



SHAREABLE PDF

# Withdrawal of inhaled corticosteroids in COPD

James D. Chalmers<sup>1</sup> and Marc Miravittles<sup>2</sup> 

**Affiliations:** <sup>1</sup>School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.  
<sup>2</sup>Pneumology Dept, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

**Correspondence:** Marc Miravittles, Pneumology Dept, University Hospital Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron 119–129, 08035 Barcelona, Spain. E-mail: marcmm@separ.es



@ERSpublications

ICS can be withdrawn in COPD patients without history of exacerbations <https://bit.ly/2TorQZd>

**Cite this article as:** Chalmers JD, Miravittles M. Withdrawal of inhaled corticosteroids in COPD. *Eur Respir J* 2020; 56: 2001778 [<https://doi.org/10.1183/13993003.01778-2020>].

This single-page version can be shared freely online.

## *From the authors:*

We thank A. Agusti for his interest in the European Respiratory Society (ERS) guideline on withdrawal of inhaled corticosteroids (ICS) in COPD [1]. He raises an important concern, that we might be recommending discontinuing a potentially effective treatment. This was carefully considered by the panel and there are important reasons to be sure that this is not the case.